Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions [MoA] - N0000193994

Name: Table of NDC products with glycoprotein 100 peptide-human leukocyte antigen-directed antibody interactions
Creator: U.S. Food & Drug Administration
License: https://creativecommons.org/licenses/by-nc-sa/4.0/

Pharmacologic Class Information

Pharmacologic Code	N0000193994
Pharmacologic Name	Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions
Pharmacologic Uses	bispecific gp100 peptide-HLA-directed CD3 T cell engager
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions

The table contains 1 products whose active ingredient are classified under the same pharmacologic class Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions [MoA].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	80446-401	Kimmtrak	Non-Proprietary Name: Tebentafusp	Injection, Solution, Concentrate	Intravenous	Immunocore Commercial Llc	ACTIVE